Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Prevalence of NRG1 Fusions in Lung Cancer

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.

Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer

April 26th 2024

Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Dr Arianna Gianakos: Innovation and Trailblazing Paths in Orthobiologics

April 23rd 2024

Arianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship Stories

April 15th 2024

Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

April 10th 2024

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

April 8th 2024

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Dr Ip on the Implications of NGS Plus Machine Learning for Diagnosing Hematologic Malignancies

April 4th 2024

Andrew Ip, MD, discusses the implications of using next-generation sequencing alongside machine learning in the diagnosis of hematologic malignancies.

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4th 2024

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

April 2nd 2024

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care

April 1st 2024

A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

All Eyes Are on IL-15 in Early Phase Studies

March 29th 2024

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors

March 27th 2024

MK-1084 had an acceptable toxicity profile when administered as a monotherapy in patients with KRAS G12C–mutated previously treated solid malignancies.

Capivasertib/Fulvestrant Wins Approval in Japan for Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

March 27th 2024

Capivasertib plus fulvestrant has been approved in Japan for pretreated, PIK3CA-, AKT1-, or PTEN-altered, HR-positive, HER2-negative breast cancer.

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

March 22nd 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Dr Masters on the 2024 ACRO Summit

March 21st 2024

Adrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.